Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable esophageal cancer
ChiCTR2400086884Phase 2Completed
- Sponsor
- Tengzhou Central People's Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and cisplatin in esophageal cancer, sponsored by Tengzhou Central People's Hospital. Primary endpoint: Pathological complete remission rate. Started Jul 2024; status: completed.
02
Drugs
camrelizumabpaclitaxelcisplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2400086884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086884.